These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3907279)

  • 41. Zuclopenthixol and perphenazine in patients with acute psychotic states. A double-blind multicentre study.
    Remvig J; Larsen H; Rask P; Skausig OB; Skov S; Strömgren LS
    Pharmacopsychiatry; 1987 Jul; 20(4):147-54. PubMed ID: 3615572
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations.
    Knudsen P
    Acta Psychiatr Scand Suppl; 1985; 322():51-75. PubMed ID: 2866666
    [TBL] [Abstract][Full Text] [Related]  

  • 43. BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia.
    Fitzgerald PB
    Curr Opin Investig Drugs; 2010 Jan; 11(1):92-100. PubMed ID: 20047163
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss.
    Andersen TH; Bech P; Larsen NE
    Nord J Psychiatry; 2005; 59(3):205-8. PubMed ID: 16195121
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gas chromatographic determination of amitriptyline, nortriptyline and perphenazine in plasma of schizophrenic patients after administration of the combination of amitriptyline with perphenazine.
    Cooper S; Albert JM; Dugal R; Bertrand M; Elie R
    Arzneimittelforschung; 1979; 29(1):158-61. PubMed ID: 582110
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A two year trial of loxapine succinate in chronic psychotic patients.
    Simpson GM; Branchey MH; Lee JH; Varga E
    Dis Nerv Syst; 1976 May; 37(5):305-7. PubMed ID: 816626
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Study of the clinical effects of sulpiride and perphenazine in 82 schizophrenic patients by the double blind method].
    Asada S; Ishimaru T; Kubo S; Kodama H; Masuda K
    Encephale; 1976; 2(1):73-83. PubMed ID: 770152
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Report on the clinical testing of the delayed-action form of the neuroleptic agent moperone hydrochloride in 20 chronic psychotic patients].
    Lydecken K
    Schweiz Arch Neurol Neurochir Psychiatr; 1977; 120(1):75-82. PubMed ID: 323966
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Double-blind comparison of bromperidol and perphenazine.
    Woggon B; Angst J
    Int Pharmacopsychiatry; 1978; 13(3):165-76. PubMed ID: 355182
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Studies on the long acting neuroleptic agent flupenthixol decanoate--a review (author's transl)].
    Sieberns S
    Pharmakopsychiatr Neuropsychopharmakol; 1978 Jul; 11(4):186-98. PubMed ID: 674354
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects.
    Hansen LB; Larsen NE; Vestergård P
    Psychopharmacology (Berl); 1981; 74(4):306-9. PubMed ID: 6794071
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics.
    Larsen EB; Gerlach J
    Acta Psychiatr Scand; 1996 May; 93(5):381-8. PubMed ID: 8792909
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Zuclopenthixol decanoate in maintenance treatment of schizophrenic outpatients. Minimum effective dose and corresponding serum levels.
    Solgaard T; Kistrup K; Aaes-Jørgensen T; Gerlach J
    Pharmacopsychiatry; 1994 May; 27(3):119-23. PubMed ID: 8078952
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prediction of the optimal perphenazine decanoate dose based on blood samples drawn within the first three weeks.
    Larsen NE; Hansen LB
    Ther Drug Monit; 1989 Nov; 11(6):642-6. PubMed ID: 2595744
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Therapy control of perphenazine in paranoid conditions. 1. Organizational aspects].
    Rask PH; Krarup G; Kragh-Sørensen P; Andersen E; Brøsen K; Gerholt F; Glue P; Hørder M; Kjeldsen CS; Klitgaard NA
    Ugeskr Laeger; 1991 Aug; 153(34):2336-9. PubMed ID: 1897042
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pipamperone (Dipiperon), a useful sedative neuroleptic drug in troublesome chronic psychotic patients.
    Squelart P; Saravia J
    Acta Psychiatr Belg; 1977; 77(2):284-93. PubMed ID: 906888
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug-responsive symptoms during early neuroleptic treatment.
    Mazure CM; Nelson JC; Jatlow PI; Bowers MB
    Psychiatry Res; 1992 Feb; 41(2):147-54. PubMed ID: 1574541
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The relationship between perphenazine plasma levels and clinical response in acute schizophrenia.
    Omérov M; Wistedt B; Bolvig-Hansen L; Larsen NE
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(1-2):159-66. PubMed ID: 2664884
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of efficacy of a new butyrophenone derivative, timiperone and perphenazine in schizophrenia by a multicentre controlled study.
    Takahashi R; Inanaga K; Samejima K; Sarai K; Asada S; Otsuki S; Nakano S
    J Int Med Res; 1982; 10(4):257-67. PubMed ID: 6126413
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Early detection of neuroleptic-induced parkinsonism in elderly patients with dementia.
    Sweet RA; Pollock BG; Rosen J; Mulsant BH; Altieri LP; Perel JM
    J Geriatr Psychiatry Neurol; 1994; 7(4):251-3. PubMed ID: 7826496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.